Neostigmine for Treating Acute Colonic Pseudo-Obstruction in Neurocritically Ill Patients
10.3988/jcn.2021.17.4.563
- Author:
Tae Jung KIM
1
;
Luis TORRES
;
Atzhiry PAZ
;
Ji Sung LEE
;
Soo-Hyun PARK
;
Huimahn Alex CHOI
;
Sang-Bae KO
Author Information
1. Department of Neurology, Seoul National University Hospital, Seoul, Korea.
- Publication Type:ORIGINAL ARTICLE
- From:Journal of Clinical Neurology
2021;17(4):563-569
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:and PurposeAcute colonic pseudo-obstruction (ACPO) is a common but understudied complication in neurocritically ill patients. The acetylcholinesterase inhibitor neostigmine can be used to treat ACPO in patients who do not respond to conventional treatment. This study investigated the effectiveness and adverse events when using neostigmine to manage ACPO in neurocritically ill patients.
Methods:This retrospective study investigated patients with ACPO who were treated using neostigmine in the neurological intensive-care units at two centers between March 2017 and August 2020. Neostigmine was administered intravenously or subcutaneously (at doses ranging from 0.25 mg to 2 mg) according to the protocols at the two centers. The outcomes were bowel movements and the changes in colon diameters on abdominal radiographs. Safety events such as bradycardia, vomiting, salivation, and sweating were evaluated.
Results:This study included 31 subjects with a mean age of 46.8 years (65.4% males). All patients had a bowel movement at a median of 120 minutes after administering neostigmine. The colon diameter decreased by a median of 17.5 mm (paired t-test: p<0.001) regardless of the dose and treatment protocols. Multilevel analysis confirmed that the mean colon diameter decreased from 66 mm pretreatment to 47.5 mm posttreatment (p<0.001), with an intraclass correlation coefficient of 13%. Three patients (9.7%) exhibited hypersalivation, sweating, bradycardia, and vomiting. Bradycardia (heart rate, 42 beats/minute) occurred in one patient (3.2%), and was successfully managed by injecting atropine.
Conclusions:Neostigmine injection is a safe and effective treatment option for ACPO in neurocritically ill patients who fail to respond to conservative management.
